Anjana Lalla

• Responsible for leading and developing early- and launch-ready materials to support brand and portfolio strategy, delivering systematic literature reviews, 20+ indirect treatment comparison studies (network meta-analyses) and 10+ health economic models leading to positive reimbursement globally for 5+ assets
• Collaborate with cross-functional teams to develop strategies; generate and communicate evidence plan to optimize patient access and demonstrate value of assets to payers, HCPs and patients.
• Manage multiple HEOR projects/assets simultaneously starting alongside Phase II clinical trials to assess potential asset value at early stage of development; identify opportunities for evidence generation and inform inclusion of COA/PRO and design of Phase III trials.
• Experience working across several disease areas across neuroscience (Migraine, Parkinson's Disease, Alzheimer's disease, post-stroke spasticity, overactive bladder, essential tremor, ALS), immunology(Crohn's disease, Ulcerative Colitis, lupus) and oncology (multiple myeloma)
• Support global market access affiliates for HTA (CADTH, NICE, NoMA, PBAC) dossier submission, provide methodological expertise and lead the response to HTA and regulatory clarification questions
• Use multi-disciplinary approach and innovative techniques to demonstrate value, e.g., vignette based utility elicitation contributing to huge impacts on access and favorable pricing
• Expertise in training field teams to communicate product value
• Manage vendors including request for proposal, review scope, and budget

Key Contributions:

• Led the successful turn-around of the ICER review of acute migraine medication by demonstrating and personally communicating with the ICER team its value using relevant clinical trial data in the economic model, resulting in more than doubling the initial estimate of value-based price calculated by ICER in the US
• Developed strong evidence to mitigate access issues for several assets impacting several million US commercial lives, by working closely with field teams
• Key partner for regulatory and HTA (NICE, CADTH, NoMA, PBAC) submissions, close engagement with HTA strategy, affiliates/field teams and market access colleagues throughout submission process to define submission strategy, pivot game plan due to roadblocks and have solutions-driven approach to ensure positive recommendation in EU and Canada
• Led HTA submissions for treatment of Parkinson's disease in UK and Canada
• Ensure operational excellence by improving ways of working across several therapeutic areas and identify KPIs that can help with achieving optimal engagement cross-functionally.

• Responsible for leading and developing 20+ US and global systematic literature reviews, indirect treatment comparison studies and health economic models to support pharmaceutical clients and vendor companies
• Created 10+ value communication tools to be used by field personnel.

• Primary investigator responsible for overseeing creation of integrated evidence plans (IEPs) and continuously updating them for several pharmaceutical clients, ensuring comprehensive evidence packages will be available for successful regulatory and HTA submission
• Excellent ability to work in matrix environment, managing several HEOR projects including US and global cost-effectiveness models, budget impact and cost consequence models, systematic and targeted literature reviews (clinical, economic, utility), indirect treatment comparisons, matching-adjusted indirect comparisons, claims database analysis, surveys, AMCP dossier/GVD and value communication tools
• 7 years' experience managing clients and leading business development efforts: responding to request for proposals, tracking and reporting financial performance of projects, including project effort and profitability
• Mentored/managed HEOR researchers/consultants while managing multiple project timelines
• Strategic leader helping clients in development and execution of HEOR strategy and identify gaps that have biggest impact on value throughout product lifecycle
• Developed KPIs that need to be met quarterly to improve project delivery using CQI approach
• Conducted several advisory boards with KOLs and patient advocacy groups to understand key value factors
• Assisted clients in defining economic and PRO outcomes to be included in Phase III clinical trials
• Experience in extensive therapeutic areas including but not limited to oncology, cardiology, and hematology.

• Project lead for 5+ disease management and quality improvement projects involving population measurement, stratification, and data analysis
• Defined and developed methods for program measurement and worked with clinicians to establish quantitative (utilization/cost) and qualitative goals for upcoming annual evaluation
• Responsible for data collection and cleaning, defining and measuring outcomes, reporting results, and documenting information needed for NCQA and other regulatory agencies.

• Project lead and primary researcher for real-world database analysis projects involving design of study, database set up, analysis plan, and reports/presentations to clients
• Developed and validated algorithm to identify transplant recipients in 7 private and 2 public payer (Medicaid) claims databases covering 15 million covered lives over 10 years
• Developed and conducted statistical analysis for various retrospective database studies using a variety of statistical methods, including univariate / multivariate linear regression, logistic regression, Kaplan-Meier product limit and Cox proportional hazards model for survival analysis and propensity score sample selection bias correction
• Designed statistical and analytical plan of study proposals for submission to the Institutional Review Board (IRB).